MedTrace Logo

Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults

NCT05500898 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2022-08-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate drug-drug interaction by comparing the pharmacokinetics (PK)/pharmacodynamics (PD), safety, and tolerability of single/multiple doses of DWP16001 , DWC202204 and DWC202205 alone or in combination in healthy male adults.

Conditions

  • Healthy

Interventions

DRUG

DWP16001

Tablets, Oral, multiple doses of DWP16001

DRUG

DWC202204+DWC202205

Tablets, Oral, multiple doses of DWC202204 and DWC202205 in combination

DRUG

DWP16001+DWC202204+DWC202205

Tablets, Oral, DWP16001 , multiple doses of DWC202204 and DWC202205 in combination

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-26
Primary Completion
2022-10-31
Completion
2023-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05500898 on ClinicalTrials.gov